All patients
Age < 65y (younger) Age > 65y Age > 75y (older) Asian type cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES metastasis (liver ) PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2 or IC1/2 : ≥1% of TC or IC and <50% of TC and <10% of IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) PDL1 (TPS >50%) PDL1 < 25% PDL1 >25% smoker (current or former) smoker (Current) smoker (Former) smoker (never) stage III (locally advanced) stage IIIa stage IIIb stage IV (metastatic) Teff high Teff low
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), anti-PD-(L)1 vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.42; 0.94]
CheckMate 017, 2015 0.59 [0.44; 0.79]
CheckMate 026 (PDL1>1%), 2016 1.07 [0.86; 1.33]
CheckMate 026 (PDL1>5%), 2016 1.02 [0.80; 1.30]
CheckMate 057, 2015 0.73 [0.59; 0.90]
CheckMate 078, 2019 0.68 [0.52; 0.89]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.78 [0.60; 1.02]
EMPOWER lung1 (all population), 2021 0.68 [0.53; 0.87]
EMPOWER lung1 (PDL1>50%), 2021 0.57 [0.42; 0.77]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
IMpower-130 (WT), 2019 0.79 [0.64; 0.98]
IMpower-131 (ACnP), 2020 0.88 [0.73; 1.06]
JAVELIN Lung 200 (all population), 2018 0.90 [0.75; 1.08]
JAVELIN Lung 200 (PDL1 >1%), 2018 0.90 [0.72; 1.12]
KEYNOTE-021, 2016 0.90 [0.42; 1.92]
KEYNOTE-024 (PDL1>50%), 2016 0.60 [0.41; 0.88]
KEYNOTE-042 (PDL1>1%), 2019 0.81 [0.71; 0.93]
KEYNOTE-042 (PDL1>20%), 2019 0.77 [0.64; 0.92]
KEYNOTE-042 (PDL1>50%), 2019 0.69 [0.56; 0.85]
KEYNOTE-189, 2018 0.49 [0.38; 0.64]
KEYNOTE-407, 2018 0.64 [0.49; 0.84]
MYSTIC (D ; all population), 2020 0.96 [0.81; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.76 [0.56; 1.03]
OAK (all population), 2016 0.80 [0.70; 0.92]
OAK (PDL1 TC 1/2/3), 2016 0.77 [0.64; 0.92]
ORIENT-11, 2020 0.61 [0.40; 0.93]
POPLAR, 2016 0.73 [0.53; 1.00]
0.76 [0.72 ; 0.81 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, ORIENT-11, 2020, POPLAR, 2016 29 51% 15,812 moderate critical deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
CheckMate 078, 2019 0.75 [0.61; 0.93]
IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
KEYNOTE-021, 2016 0.71 [0.45; 1.12]
KEYNOTE-024 (PDL1>50%), 2016 0.62 [0.48; 0.81]
KEYNOTE-042 (PDL1>1%), 2019 0.80 [0.71; 0.90]
KEYNOTE-042 (PDL1>20%), 2019 0.75 [0.64; 0.88]
KEYNOTE-042 (PDL1>50%), 2019 0.98 [0.82; 1.18]
KEYNOTE-189, 2018 0.56 [0.45; 0.70]
0.73 [0.64 ; 0.83 ] CheckMate 017, 2015, CheckMate 078, 2019, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 9 65% 4,716 moderate not evaluable PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
CheckMate 078, 2019 0.79 [0.64; 0.97]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
KEYNOTE-021, 2016 0.54 [0.35; 0.83]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.39; 0.65]
KEYNOTE-042 (PDL1>1%), 2019 1.05 [0.93; 1.18]
KEYNOTE-042 (PDL1>20%), 2019 0.95 [0.82; 1.10]
KEYNOTE-042 (PDL1>50%), 2019 0.85 [0.71; 1.01]
KEYNOTE-189, 2018 0.48 [0.40; 0.58]
0.69 [0.57 ; 0.83 ] CheckMate 017, 2015, CheckMate 078, 2019, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 11 88% 5,598 moderate critical progression or deaths (PFS)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.71 [0.49; 1.03]
CheckMate 017, 2015 0.62 [0.47; 0.81]
CheckMate 026 (PDL1>1%), 2016 1.17 [0.95; 1.44]
CheckMate 026 (PDL1>5%), 2016 1.15 [0.91; 1.45]
CheckMate 057, 2015 0.92 [0.77; 1.10]
CheckMate 078, 2019 0.77 [0.62; 0.95]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.73 [0.56; 0.95]
EMPOWER lung1 (all population), 2021 0.59 [0.49; 0.72]
EMPOWER lung1 (PDL1>50%), 2021 0.54 [0.43; 0.68]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
IMpower-130 (WT), 2019 0.64 [0.54; 0.76]
IMpower-131 (ACnP), 2020 0.71 [0.60; 0.85]
JAVELIN Lung 200 (all population), 2018 1.16 [0.97; 1.39]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.01 [0.80; 1.28]
KEYNOTE-021, 2016 0.53 [0.31; 0.91]
KEYNOTE-024 (PDL1>50%), 2016 0.50 [0.37; 0.68]
KEYNOTE-042 (PDL1>1%), 2019 1.07 [0.94; 1.21]
KEYNOTE-042 (PDL1>20%), 2019 0.94 [0.80; 1.11]
KEYNOTE-042 (PDL1>50%), 2019 0.81 [0.67; 0.98]
KEYNOTE-189, 2018 0.52 [0.43; 0.63]
KEYNOTE-407, 2018 0.56 [0.45; 0.70]
MYSTIC (D ; PDL1>25%), 2020 0.87 [0.59; 1.29]
OAK (all population), 2016 0.96 [0.85; 1.08]
OAK (PDL1 TC 1/2/3), 2016 0.87 [0.74; 1.03]
ORIENT-11, 2020 0.48 [0.36; 0.64]
POPLAR, 2016 0.94 [0.72; 1.23]
0.76 [0.69 ; 0.84 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, ORIENT-11, 2020, POPLAR, 2016 28 84% 15,066 moderate critical DORdetailed results IMpower-130 (WT), 2019 2.41 [1.27; 4.60]
IMpower-131 (ACnP), 2020 2.14 [1.13; 4.04]
OAK (PDL1 TC 1/2/3), 2016 9.61 [3.07; 30.08]
3.18 [1.53 ; 6.61 ] IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, OAK (PDL1 TC 1/2/3), 2016 3 63% 708 moderate not evaluable objective responses (ORR)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.87 [1.55; 9.69]
CheckMate 017, 2015 2.60 [1.26; 5.35]
CheckMate 026 (PDL1>5%), 2016 0.70 [0.46; 1.06]
CheckMate 057, 2015 1.70 [1.11; 2.61]
CheckMate 078, 2019 4.40 [1.99; 9.74]
EMPOWER lung1 (all population), 2021 2.21 [1.58; 3.10]
EMPOWER lung1 (PDL1>50%), 2021 2.53 [1.32; 4.85]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
IMpower-130 (WT), 2019 2.07 [1.48; 2.89]
IMpower-131 (ACnP), 2020 1.42 [1.05; 1.92]
JAVELIN Lung 200 (all population), 2018 1.40 [0.92; 2.13]
JAVELIN Lung 200 (PDL1 >1%), 2018 1.76 [1.08; 2.86]
KEYNOTE-021, 2016 3.06 [1.45; 6.45]
KEYNOTE-024 (PDL1>50%), 2016 2.11 [1.31; 3.39]
KEYNOTE-042 (PDL1>1%), 2019 1.04 [0.81; 1.33]
KEYNOTE-042 (PDL1>20%), 2019 1.24 [0.92; 1.66]
KEYNOTE-042 (PDL1>50%), 2019 1.39 [0.99; 1.94]
KEYNOTE-189, 2018 3.88 [2.61; 5.79]
KEYNOTE-407, 2018 2.20 [1.57; 3.09]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.43]
OAK (all population), 2016 1.19 [0.85; 1.67]
OAK (PDL1 TC 1/2/3), 2016 1.41 [0.93; 2.14]
ORIENT-11, 2020 2.54 [1.63; 3.97]
POPLAR, 2016 0.99 [0.52; 1.91]
1.62 [1.37 ; 1.93 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>5%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, EMPOWER lung1 (PDL1>50%), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, IMpower-130 (WT), 2019, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, JAVELIN Lung 200 (PDL1 >1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, ORIENT-11, 2020, POPLAR, 2016 26 76% 14,156 moderate critical objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
CheckMate 078, 2019 4.80 [2.14; 10.77]
IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
KEYNOTE-021, 2016 2.80 [1.34; 5.83]
KEYNOTE-024 (PDL1>50%), 2016 1.89 [1.19; 3.02]
KEYNOTE-042 (PDL1>1%), 2019 1.03 [0.81; 1.32]
KEYNOTE-042 (PDL1>20%), 2019 1.21 [0.90; 1.62]
KEYNOTE-042 (PDL1>50%), 2019 1.35 [0.96; 1.88]
KEYNOTE-189, 2018 3.84 [2.58; 5.70]
1.74 [1.21 ; 2.51 ] CheckMate 017, 2015, CheckMate 078, 2019, IMpower-110 (TC3 or IC3), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-042 (PDL1>20%), 2019, KEYNOTE-042 (PDL1>50%), 2019, KEYNOTE-189, 2018 9 84% 4,716 moderate not evaluable AE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.24 [0.01; 5.43]
CheckMate 057, 2015 0.31 [0.20; 0.48]
EMPOWER lung1 (all population), 2021 0.18 [0.12; 0.27]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
IMpower-131 (ACnP), 2020 5.12 [1.11; 23.56]
KEYNOTE-189, 2018 4.04 [0.36; 44.82]
KEYNOTE-407, 2018 1.20 [0.36; 3.96]
MYSTIC (D ; all population), 2020 0.59 [0.31; 1.13]
MYSTIC (D ; PDL1>25%), 2020 0.42 [0.14; 1.22]
OAK (all population), 2016 0.66 [0.39; 1.13]
ORIENT-11, 2020 1.02 [0.03; 30.46]
POPLAR, 2016 0.87 [0.26; 2.93]
0.59 [0.36 ; 0.96 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, POPLAR, 2016 12 73% 6,655 moderate critical AE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.36 [0.18; 0.75]
CheckMate 057, 2015 0.42 [0.29; 0.59]
EMPOWER lung1 (all population), 2021 0.19 [0.13; 0.29]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
IMpower-131 (ACnP), 2020 1.37 [0.98; 1.90]
KEYNOTE-189, 2018 1.03 [0.73; 1.45]
KEYNOTE-407, 2018 0.99 [0.70; 1.39]
MYSTIC (D ; all population), 2020 0.81 [0.60; 1.10]
MYSTIC (D ; PDL1>25%), 2020 0.91 [0.58; 1.41]
OAK (all population), 2016 0.51 [0.41; 0.65]
ORIENT-11, 2020 1.13 [0.74; 1.73]
POPLAR, 2016 0.60 [0.38; 0.97]
0.64 [0.47 ; 0.88 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, POPLAR, 2016 12 89% 6,655 moderate low AE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 3.27 [0.63; 16.86]
EMPOWER lung1 (all population), 2021 1.24 [0.46; 3.38]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
IMpower-131 (ACnP), 2020 2.59 [1.36; 4.92]
KEYNOTE-189, 2018 1.13 [0.56; 2.28]
KEYNOTE-407, 2018 1.31 [0.69; 2.49]
MYSTIC (D ; all population), 2020 0.82 [0.38; 1.75]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.20; 2.86]
OAK (all population), 2016 0.67 [0.30; 1.53]
ORIENT-11, 2020 0.31 [0.11; 0.90]
POPLAR, 2016 1.15 [0.34; 3.85]
1.08 [0.76 ; 1.52 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, POPLAR, 2016 11 40% 6,100 moderate low AE leading to treatment discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.63 [0.24; 1.67]
EMPOWER lung1 (all population), 2021 1.62 [0.82; 3.21]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
IMpower-131 (ACnP), 2020 2.09 [1.45; 3.02]
KEYNOTE-189, 2018 2.19 [1.31; 3.65]
KEYNOTE-407, 2018 2.28 [1.45; 3.61]
MYSTIC (D ; all population), 2020 0.72 [0.47; 1.12]
MYSTIC (D ; PDL1>25%), 2020 0.75 [0.38; 1.46]
OAK (all population), 2016 0.58 [0.45; 0.75]
ORIENT-11, 2020 0.70 [0.31; 1.55]
POPLAR, 2016 0.29 [0.14; 0.61]
0.90 [0.58 ; 1.40 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, ORIENT-11, 2020, POPLAR, 2016 11 88% 6,100 moderate low AE leading to treatment discontinuation (grade 3-4)detailed results KEYNOTE-189, 2018 2.04 [1.16; 3.59]
KEYNOTE-407, 2018 2.09 [1.28; 3.39]
MYSTIC (D ; all population), 2020 1.10 [0.64; 1.89]
ORIENT-11, 2020 0.64 [0.26; 1.56]
1.43 [0.89 ; 2.29 ] KEYNOTE-189, 2018, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 4 61% 2,283 low not evaluable SAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.73 [0.81; 3.73]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
IMpower-131 (ACnP), 2020 2.28 [1.66; 3.14]
MYSTIC (D ; PDL1>25%), 2020 1.22 [0.77; 1.94]
POPLAR, 2016 1.05 [0.64; 1.73]
1.38 [0.94 ; 2.01 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, MYSTIC (D ; PDL1>25%), 2020, POPLAR, 2016 5 72% 1,933 moderate not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
OAK (all population), 2016 1.03 [0.80; 1.31]
0.34 [0.03 ; 3.42 ] CheckMate 017, 2015, OAK (all population), 2016 2 93% 1,447 moderate not evaluable STRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.33; 3.10]
CheckMate 017, 2015 0.23 [0.11; 0.51]
CheckMate 026 (PDL1>1%), 2016 0.93 [0.60; 1.46]
CheckMate 057, 2015 0.32 [0.19; 0.55]
CheckMate 078, 2019 0.59 [0.34; 1.02]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.75 [1.00; 3.09]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
IMpower-131 (ACnP), 2020 2.27 [1.46; 3.51]
JAVELIN Lung 200 (all population), 2018 0.37 [0.24; 0.57]
KEYNOTE-021, 2016 3.47 [1.25; 9.62]
KEYNOTE-024 (PDL1>50%), 2016 1.05 [0.60; 1.82]
MYSTIC (D ; all population), 2020 0.56 [0.35; 0.90]
MYSTIC (D ; PDL1>25%), 2020 0.38 [0.18; 0.77]
0.73 [0.48 ; 1.11 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020 13 85% 5,753 moderate low STRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.82 [0.50; 1.33]
CheckMate 057, 2015 0.25 [0.14; 0.46]
CheckMate 078, 2019 0.34 [0.18; 0.66]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.05 [1.12; 3.76]
KEYNOTE-021, 2016 5.56 [1.49; 20.67]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.55; 1.72]
MYSTIC (D ; all population), 2020 0.48 [0.28; 0.84]
0.79 [0.43 ; 1.46 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, MYSTIC (D ; all population), 2020 7 85% 3,079 moderate not evaluable TRAE (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.19 [0.08; 0.46]
CheckMate 017, 2015 0.22 [0.12; 0.41]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.12; 0.34]
CheckMate 078, 2019 0.35 [0.22; 0.57]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 3.42 [1.76; 6.65]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
IMpower-131 (ACnP), 2020 1.80 [0.98; 3.28]
JAVELIN Lung 200 (all population), 2018 0.29 [0.21; 0.42]
KEYNOTE-021, 2016 0.95 [0.29; 3.12]
KEYNOTE-024 (PDL1>50%), 2016 0.31 [0.16; 0.58]
KEYNOTE-042 (PDL1>1%), 2019 0.19 [0.14; 0.26]
MYSTIC (D ; all population), 2020 0.24 [0.17; 0.34]
MYSTIC (D ; PDL1>25%), 2020 0.21 [0.12; 0.38]
OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.35 [0.25 ; 0.50 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, POPLAR, 2016 15 87% 7,913 moderate low TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.13 [0.05; 0.36]
CheckMate 017, 2015 0.06 [0.03; 0.13]
CheckMate 026 (PDL1>1%), 2016 0.21 [0.14; 0.31]
CheckMate 057, 2015 0.10 [0.06; 0.16]
CheckMate 078, 2019 0.15 [0.10; 0.24]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.35 [1.53; 3.60]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
IMpower-131 (ACnP), 2020 1.57 [1.14; 2.15]
JAVELIN Lung 200 (all population), 2018 0.12 [0.08; 0.18]
KEYNOTE-021, 2016 2.04 [0.92; 4.52]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.20; 0.51]
KEYNOTE-042 (PDL1>1%), 2019 0.30 [0.23; 0.39]
MYSTIC (D ; all population), 2020 0.34 [0.24; 0.49]
MYSTIC (D ; PDL1>25%), 2020 0.36 [0.22; 0.61]
OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.29 [0.18 ; 0.47 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, POPLAR, 2016 16 95% 8,468 moderate low TRAE leading to death (grade 5)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 078, 2019 0.61 [0.14; 2.77]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 4.33 [0.48; 39.16]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
IMpower-131 (ACnP), 2020 1.34 [0.30; 6.02]
JAVELIN Lung 200 (all population), 2018 0.19 [0.05; 0.68]
KEYNOTE-021, 2016 0.52 [0.05; 5.86]
KEYNOTE-024 (PDL1>50%), 2016 0.32 [0.03; 3.11]
KEYNOTE-042 (PDL1>1%), 2019 0.90 [0.42; 1.92]
KEYNOTE-407, 2018 1.70 [0.61; 4.75]
MYSTIC (D ; all population), 2020 0.63 [0.11; 3.82]
MYSTIC (D ; PDL1>25%), 2020 0.95 [0.06; 15.32]
OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.76 [0.50 ; 1.16 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-407, 2018, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, OAK (all population), 2016, POPLAR, 2016 15 0% 7,941 moderate low TRAE leading to discontinuation (any grade)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.24; 4.26]
CheckMate 017, 2015 0.28 [0.09; 0.89]
CheckMate 026 (PDL1>1%), 2016 0.70 [0.41; 1.20]
CheckMate 078, 2019 0.66 [0.32; 1.37]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.89 [0.48; 1.63]
JAVELIN Lung 200 (all population), 2018 0.47 [0.29; 0.77]
KEYNOTE-021, 2016 0.76 [0.25; 2.35]
KEYNOTE-024 (PDL1>50%), 2016 0.64 [0.29; 1.44]
KEYNOTE-042 (PDL1>1%), 2019 0.95 [0.64; 1.39]
MYSTIC (D ; all population), 2020 0.55 [0.31; 0.99]
MYSTIC (D ; PDL1>25%), 2020 0.47 [0.21; 1.04]
POPLAR, 2016 0.07 [0.02; 0.29]
0.61 [0.46 ; 0.80 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, MYSTIC (D ; PDL1>25%), 2020, POPLAR, 2016 12 43% 5,509 moderate critical TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
CheckMate 026 (PDL1>1%), 2016 1.24 [0.64; 2.40]
CheckMate 078, 2019 0.80 [0.33; 1.95]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.80 [0.38; 1.70]
KEYNOTE-021, 2016 4.44 [0.48; 40.91]
KEYNOTE-024 (PDL1>50%), 2016 0.86 [0.32; 2.29]
KEYNOTE-042 (PDL1>1%), 2019 1.09 [0.71; 1.66]
MYSTIC (D ; all population), 2020 1.28 [0.60; 2.75]
1.02 [0.78 ; 1.33 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 8 0% 4,035 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
1.49 [0.30 ; 7.48 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 5 0% 2,052 moderate serious Adrenal insufficiency TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
KEYNOTE-189, 2018 0.50 [0.03; 8.00]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
1.63 [0.44 ; 6.05 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 6 0% 4,130 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
0.51 [0.15 ; 1.74 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 0% 5,357 moderate serious Anaemia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
CheckMate 017, 2015 0.12 [0.01; 2.29]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.13]
CheckMate 057, 2015 0.13 [0.02; 1.07]
CheckMate 078, 2019 0.15 [0.02; 1.47]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.34 [0.75; 2.38]
IMpower-131 (ACnP), 2020 1.09 [0.76; 1.58]
JAVELIN Lung 200 (all population), 2018 0.03 [0.00; 0.44]
KEYNOTE-021, 2016 0.79 [0.27; 2.29]
KEYNOTE-024 (PDL1>50%), 2016 0.08 [0.02; 0.28]
KEYNOTE-042 (PDL1>1%), 2019 0.04 [0.02; 0.12]
MYSTIC (D ; all population), 2020 0.01 [0.00; 0.19]
0.15 [0.06 ; 0.39 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 12 87% 6,141 moderate critical Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.81 [0.15 ; 4.41 ] CheckMate 017, 2015, CheckMate 057, 2015, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 5 0% 3,492 moderate serious Asthenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
CheckMate 017, 2015 0.10 [0.01; 1.76]
CheckMate 026 (PDL1>1%), 2016 0.12 [0.01; 2.31]
CheckMate 057, 2015 0.15 [0.02; 1.28]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.07; 17.15]
IMpower-131 (ACnP), 2020 0.77 [0.28; 2.10]
JAVELIN Lung 200 (all population), 2018 0.06 [0.01; 0.49]
KEYNOTE-042 (PDL1>1%), 2019 0.29 [0.08; 1.05]
MYSTIC (D ; all population), 2020 0.12 [0.01; 0.94]
0.29 [0.15 ; 0.56 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 9 7% 5,223 moderate serious Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.49 [0.02; 14.58]
0.86 [0.17 ; 4.48 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 5 0% 2,003 moderate not evaluable Colitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 8.08 [0.43; 153.53]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
KEYNOTE-024 (PDL1>50%), 2016 3.93 [0.18; 87.97]
KEYNOTE-042 (PDL1>1%), 2019 3.89 [0.43; 34.87]
KEYNOTE-189, 2018 3.01 [0.15; 60.33]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
2.83 [1.11 ; 7.23 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 11 0% 6,728 moderate critical Constipation TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.23 [0.01; 5.17]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.26 [0.01; 5.89]
IMpower-131 (ACnP), 2020 0.50 [0.02; 14.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
MYSTIC (D ; all population), 2020 0.48 [0.02; 14.24]
0.55 [0.18 ; 1.69 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 10 0% 4,890 moderate critical Decreased appetite TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
CheckMate 017, 2015 0.98 [0.06; 15.91]
CheckMate 026 (PDL1>1%), 2016 0.24 [0.03; 2.19]
CheckMate 057, 2015 0.15 [0.01; 3.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.43 [0.32; 6.48]
IMpower-131 (ACnP), 2020 3.41 [0.93; 12.49]
JAVELIN Lung 200 (all population), 2018 0.07 [0.00; 1.15]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.12 [0.01; 2.27]
KEYNOTE-042 (PDL1>1%), 2019 0.53 [0.18; 1.60]
MYSTIC (D ; all population), 2020 0.24 [0.03; 2.13]
0.61 [0.30 ; 1.23 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 12 20% 6,141 moderate low Dermatitis acneiform TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
IMpower-131 (ACnP), 2020 6.05 [0.30; 121.16]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.52 [0.36 ; 6.44 ] CheckMate 057, 2015, CheckMate 078, 2019, IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 6 0% 3,348 moderate serious Diarrhoea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 026 (PDL1>1%), 2016 0.59 [0.14; 2.48]
CheckMate 057, 2015 0.62 [0.10; 3.74]
CheckMate 078, 2019 0.93 [0.03; 27.74]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.15; 7.64]
EMPOWER lung1 (all population), 2021 0.48 [0.02; 14.38]
IMpower-131 (ACnP), 2020 1.44 [0.54; 3.83]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 3.00 [0.60; 15.11]
KEYNOTE-042 (PDL1>1%), 2019 4.87 [0.57; 41.77]
MYSTIC (D ; all population), 2020 0.95 [0.13; 6.81]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.03 [0.61 ; 1.76 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 14 0% 7,235 moderate low Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
1.02 [0.06 ; 16.40 ] CheckMate 017, 2015, KEYNOTE-021, 2016 2 0% 381 moderate not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.98 [0.14 ; 7.02 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016 4 0% 1,510 moderate not evaluable Dyspepsia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.50 [0.02; 15.30]
0.50 [0.02 ; 15.30 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1 0% 125 NA not evaluable Dyspnoea TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.04; 5.13]
0.46 [0.04 ; 5.13 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 0.09 [0.01; 0.73]
CheckMate 026 (PDL1>1%), 2016 0.20 [0.06; 0.71]
CheckMate 057, 2015 0.21 [0.06; 0.74]
CheckMate 078, 2019 0.27 [0.06; 1.15]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.18 [0.65; 7.39]
IMpower-131 (ACnP), 2020 1.89 [0.75; 4.80]
JAVELIN Lung 200 (all population), 2018 0.09 [0.01; 0.71]
KEYNOTE-021, 2016 4.32 [0.19; 97.73]
KEYNOTE-024 (PDL1>50%), 2016 0.38 [0.07; 2.00]
KEYNOTE-042 (PDL1>1%), 2019 0.36 [0.09; 1.36]
MYSTIC (D ; all population), 2020 0.81 [0.27; 2.45]
0.48 [0.24 ; 0.94 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 12 58% 6,141 moderate low Febrile neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.08 [0.00; 1.41]
CheckMate 017, 2015 0.03 [0.00; 0.58]
CheckMate 057, 2015 0.02 [0.00; 0.27]
IMpower-131 (ACnP), 2020 2.66 [1.10; 6.46]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.20]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
0.13 [0.01 ; 1.42 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 6 84% 2,487 moderate serious Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.19 [0.36; 3.94]
CheckMate 078, 2019 0.93 [0.03; 27.74]
1.15 [0.37 ; 3.58 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
1.00 [0.02 ; 50.55 ] IMpower-131 (ACnP), 2020 1 0% 668 NA not evaluable Headache TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.46 [0.02 ; 13.86 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
IMpower-131 (ACnP), 2020 1.00 [0.06; 16.05]
KEYNOTE-042 (PDL1>1%), 2019 13.68 [0.77; 241.54]
KEYNOTE-189, 2018 4.02 [0.21; 76.41]
MYSTIC (D ; all population), 2020 1.91 [0.06; 57.12]
4.17 [1.42 ; 12.24 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 7 0% 4,618 moderate not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.23 [0.01; 6.90]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.44 [0.06 ; 3.38 ] CheckMate 057, 2015, CheckMate 078, 2019, JAVELIN Lung 200 (all population), 2018 3 0% 1,806 moderate not evaluable Hypertension TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 1.86 [0.17; 20.62]
1.86 [0.17 ; 20.62 ] JAVELIN Lung 200 (all population), 2018 1 0% 758 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.96 [0.32 ; 2.88 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 12 0% 6,488 moderate critical Hypophysitis TRAE (grade 3-4)detailed results KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.87 [0.33 ; 10.75 ] KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 4 0% 2,883 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 4.02 [0.18; 89.44]
JAVELIN Lung 200 (all population), 2018 1.86 [0.06; 55.60]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
MYSTIC (D ; all population), 2020 3.83 [0.17; 85.25]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.40 [0.53 ; 3.69 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 14 0% 7,776 moderate critical Increase AST TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.03; 7.42]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.35; 10.63]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.39 [0.47 ; 4.10 ] CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 6 0% 3,514 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 3.51 [0.72; 17.07]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.03; 7.42]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
JAVELIN Lung 200 (all population), 2018 3.73 [0.17; 82.97]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-042 (PDL1>1%), 2019 1.75 [0.58; 5.26]
ORIENT-11, 2020 0.49 [0.01; 24.91]
1.69 [0.80 ; 3.53 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, ORIENT-11, 2020 8 0% 4,802 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
0.99 [0.06 ; 15.95 ] CheckMate 057, 2015, KEYNOTE-021, 2016 2 0% 676 moderate not evaluable Increased lipase level TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
JAVELIN Lung 200 (all population), 2018 3.74 [0.42; 33.65]
3.14 [0.49 ; 19.89 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, JAVELIN Lung 200 (all population), 2018 2 0% 883 moderate not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.01; 23.40]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
JAVELIN Lung 200 (all population), 2018 5.64 [0.68; 47.10]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.16 [0.02; 1.33]
KEYNOTE-189, 2018 1.00 [0.03; 29.86]
0.92 [0.34 ; 2.48 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 057, 2015, CheckMate 078, 2019, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 10 0% 5,431 moderate low Leucopenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.16 [0.01; 3.32]
CheckMate 017, 2015 0.19 [0.02; 1.66]
CheckMate 026 (PDL1>1%), 2016 0.05 [0.00; 0.92]
CheckMate 057, 2015 0.02 [0.00; 0.32]
CheckMate 078, 2019 0.02 [0.00; 0.18]
IMpower-131 (ACnP), 2020 1.46 [0.72; 2.93]
JAVELIN Lung 200 (all population), 2018 0.05 [0.00; 0.78]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 0.05 [0.00; 0.82]
0.13 [0.03 ; 0.56 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019 9 75% 4,761 moderate serious Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
1.22 [0.20 ; 7.53 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021 4 0% 2,275 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.09 [0.00; 1.69]
JAVELIN Lung 200 (all population), 2018 0.11 [0.01; 2.18]
0.23 [0.04 ; 1.21 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 4 0% 2,103 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 1.87 [0.06; 55.99]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
0.79 [0.17 ; 3.73 ] CheckMate 017, 2015, CheckMate 057, 2015, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 5 0% 3,492 moderate not evaluable Myocarditis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
1.41 [0.11 ; 18.42 ] JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 2 0% 2,009 moderate not evaluable Myositis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.79 [0.08 ; 7.57 ] IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-189, 2018 3 0% 1,579 moderate not evaluable Nausea TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.25 [0.01; 5.61]
CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 026 (PDL1>1%), 2016 0.19 [0.02; 1.67]
CheckMate 057, 2015 0.93 [0.13; 6.67]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 0.85 [0.22; 3.21]
IMpower-131 (ACnP), 2020 3.55 [0.73; 17.23]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 0.16 [0.01; 3.21]
KEYNOTE-042 (PDL1>1%), 2019 0.07 [0.00; 1.21]
MYSTIC (D ; all population), 2020 0.08 [0.00; 1.41]
0.49 [0.22 ; 1.10 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 11 24% 5,648 moderate critical Nephritis TRAE (grade 3-4)detailed results EMPOWER lung1 (all population), 2021 0.96 [0.02; 48.69]
IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 1.94 [0.06; 57.80]
KEYNOTE-189, 2018 6.06 [0.34; 109.04]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
1.95 [0.47 ; 8.16 ] EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020 6 0% 4,248 moderate serious Neutropenia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 0.09 [0.01; 1.76]
CheckMate 017, 2015 0.01 [0.00; 0.15]
CheckMate 026 (PDL1>1%), 2016 0.02 [0.00; 0.25]
CheckMate 057, 2015 0.00 [0.00; 0.08]
CheckMate 078, 2019 0.03 [0.01; 0.15]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.19 [0.63; 2.24]
IMpower-131 (ACnP), 2020 0.93 [0.65; 1.35]
JAVELIN Lung 200 (all population), 2018 0.01 [0.00; 0.13]
KEYNOTE-021, 2016 2.14 [0.19; 24.25]
KEYNOTE-024 (PDL1>50%), 2016 0.02 [0.00; 0.35]
KEYNOTE-042 (PDL1>1%), 2019 0.02 [0.00; 0.14]
MYSTIC (D ; all population), 2020 0.02 [0.00; 0.18]
0.07 [0.02 ; 0.22 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 12 88% 6,141 moderate critical Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
0.63 [0.05 ; 8.17 ] CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018 2 0% 1,313 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 2.00 [0.07; 59.91]
KEYNOTE-024 (PDL1>50%), 2016 1.95 [0.07; 58.69]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 2.00 [0.09; 44.56]
1.73 [0.31 ; 9.58 ] IMpower-131 (ACnP), 2020, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 4 0% 2,830 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results KEYNOTE-021, 2016 0.52 [0.02; 15.84]
0.52 [0.02 ; 15.84 ] KEYNOTE-021, 2016 1 0% 121 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.15 [0.01; 3.09]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-131 (ACnP), 2020 2.01 [0.37; 11.06]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 1.76]
0.51 [0.18 ; 1.48 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, EMPOWER lung1 (all population), 2021, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 7 4% 4,719 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 026 (PDL1>1%), 2016 0.98 [0.02; 49.83]
CheckMate 057, 2015 0.47 [0.02; 13.95]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
0.50 [0.10 ; 2.46 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 5 0% 2,224 moderate serious Peripheral sensory neuropathy TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 4.04 [0.45; 36.31]
JAVELIN Lung 200 (all population), 2018 0.46 [0.02; 13.86]
KEYNOTE-042 (PDL1>1%), 2019 0.08 [0.00; 1.43]
0.62 [0.05 ; 7.24 ] IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-042 (PDL1>1%), 2019 3 57% 2,677 moderate not evaluable Pneumonia TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
JAVELIN Lung 200 (all population), 2018 0.09 [0.00; 1.68]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
0.53 [0.08 ; 3.32 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 3 11% 1,004 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.02; 52.03]
CheckMate 017, 2015 1.98 [0.07; 59.45]
CheckMate 057, 2015 2.82 [0.29; 27.28]
CheckMate 078, 2019 3.74 [0.20; 71.10]
EMPOWER lung1 (all population), 2021 1.93 [0.06; 57.70]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
IMpower-131 (ACnP), 2020 1.68 [0.40; 7.07]
JAVELIN Lung 200 (all population), 2018 2.80 [0.29; 27.04]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-024 (PDL1>50%), 2016 3.97 [0.44; 35.97]
KEYNOTE-042 (PDL1>1%), 2019 20.97 [2.81; 156.36]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
MYSTIC (D ; all population), 2020 3.85 [0.43; 34.59]
ORIENT-11, 2020 0.98 [0.09; 10.96]
2.30 [1.28 ; 4.12 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 14 0% 7,506 moderate low Pruritic rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 1.06 [0.02; 53.93]
KEYNOTE-021, 2016 1.05 [0.02; 53.86]
KEYNOTE-042 (PDL1>1%), 2019 3.88 [0.17; 86.15]
MYSTIC (D ; all population), 2020 0.95 [0.02; 48.21]
ORIENT-11, 2020 0.49 [0.01; 24.91]
0.97 [0.26 ; 3.61 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 8 0% 4,423 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.93 [0.02; 47.22]
JAVELIN Lung 200 (all population), 2018 0.93 [0.02; 46.93]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
0.69 [0.13 ; 3.61 ] CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018, KEYNOTE-024 (PDL1>50%), 2016 5 0% 2,407 moderate serious Rash TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 1.02 [0.06; 16.62]
CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 026 (PDL1>1%), 2016 1.98 [0.18; 21.94]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 2.79 [0.14; 56.11]
CheckMate 227 (NC vs C ; PDL1<1%), 2018 2.13 [0.07; 64.04]
EMPOWER lung1 (all population), 2021 3.87 [0.17; 86.12]
IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
IMpower-131 (ACnP), 2020 2.01 [0.18; 22.23]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
KEYNOTE-042 (PDL1>1%), 2019 5.82 [0.29; 116.52]
MYSTIC (D ; all population), 2020 2.88 [0.30; 27.79]
ORIENT-11, 2020 0.16 [0.02; 1.56]
1.44 [0.69 ; 3.00 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 017, 2015, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, CheckMate 078, 2019, CheckMate 227 (NC vs C ; PDL1<1%), 2018, EMPOWER lung1 (all population), 2021, IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020, ORIENT-11, 2020 13 0% 6,722 moderate low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 1.97 [0.07; 59.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.06 [0.08 ; 13.83 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 12.07 [0.67; 217.19]
CheckMate 078, 2019 6.60 [0.37; 116.99]
8.91 [1.16 ; 68.41 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Sepsis TRAE (grade 3-4)detailed results JAVELIN Lung 200 (all population), 2018 0.23 [0.01; 5.14]
KEYNOTE-021, 2016 2.12 [0.07; 64.42]
0.63 [0.06 ; 6.26 ] JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016 2 0% 879 moderate not evaluable Severe skin reaction TRAE (grade 3-4)detailed results IMpower-131 (ACnP), 2020 1.00 [0.02; 50.55]
KEYNOTE-021, 2016 1.05 [0.06; 17.21]
KEYNOTE-024 (PDL1>50%), 2016 12.12 [0.67; 218.98]
KEYNOTE-042 (PDL1>1%), 2019 10.81 [1.39; 83.96]
KEYNOTE-189, 2018 1.00 [0.30; 3.35]
2.45 [0.73 ; 8.21 ] IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 30% 2,951 moderate not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 026 (PDL1>1%), 2016 5.00 [0.58; 43.09]
CheckMate 078, 2019 2.79 [0.14; 56.11]
4.10 [0.71 ; 23.60 ] CheckMate 026 (PDL1>1%), 2016, CheckMate 078, 2019 2 0% 1,023 moderate not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020 2.05 [0.07; 62.21]
CheckMate 026 (PDL1>1%), 2016 0.49 [0.02; 14.72]
CheckMate 057, 2015 0.23 [0.01; 5.17]
JAVELIN Lung 200 (all population), 2018 0.15 [0.01; 3.08]
KEYNOTE-021, 2016 0.52 [0.02; 15.84]
KEYNOTE-024 (PDL1>50%), 2016 0.24 [0.01; 5.39]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
0.41 [0.12 ; 1.44 ] ARCTIC (D ; study A ; PDL1>25% EXPLORATORY), 2020, CheckMate 026 (PDL1>1%), 2016, CheckMate 057, 2015, JAVELIN Lung 200 (all population), 2018, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019 7 0% 3,644 moderate serious Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 026 (PDL1>1%), 2016 0.04 [0.01; 0.31]
IMpower-131 (ACnP), 2020 1.16 [0.68; 2.00]
KEYNOTE-021, 2016 1.05 [0.14; 7.73]
KEYNOTE-024 (PDL1>50%), 2016 0.06 [0.00; 1.02]
KEYNOTE-042 (PDL1>1%), 2019 0.10 [0.01; 0.75]
MYSTIC (D ; all population), 2020 0.03 [0.00; 0.42]
0.17 [0.04 ; 0.83 ] CheckMate 026 (PDL1>1%), 2016, IMpower-131 (ACnP), 2020, KEYNOTE-021, 2016, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, MYSTIC (D ; all population), 2020 6 78% 3,595 moderate serious Thyroiditis TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
KEYNOTE-024 (PDL1>50%), 2016 0.97 [0.02; 49.41]
KEYNOTE-042 (PDL1>1%), 2019 0.97 [0.02; 48.81]
KEYNOTE-189, 2018 0.50 [0.01; 25.20]
0.73 [0.13 ; 4.20 ] CheckMate 057, 2015, CheckMate 078, 2019, KEYNOTE-024 (PDL1>50%), 2016, KEYNOTE-042 (PDL1>1%), 2019, KEYNOTE-189, 2018 5 0% 3,210 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-07-06 00:53 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,854,374,1073,953,672,1080,862,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258
